Toujeo lowers hypoglycemia among insulin-treated people with type 2 diabetes

A new observational study has shown that Toujeo insulin reduced events of hypoglycemia by 33 per cent compared to other basal insulins.
Toujeo is a once-daily long-acting insulin made by Sanofi, the same company that makes Lantus.
The results of the DELIVER 2 study, which involved 1,894 people, were released during the Endocrine Society 2017 Annual Meeting in Orlando, Florida, US.
Riccardo Perfetti, who is head of Sanofi’s global diabetes medical team, said: “These results increase the body of evidence on the use of Toujeo in people with type 2 diabetes from observational studies.
“While randomised clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for […] evaluating how findings from clinical trials can translate into routine clinical practice.”
The DELIVER 2 trial used data from 1,894 people with type 2 diabetes to test how effective Toujeo was during a six-month period.
Patients who switched to Toujeo had a 33 per cent reduced risk of hypoglycemia and a 48 per cent reduction in hypoglycemic events that led to a hospital visits, compared to other basal insulins.
Toujeo is also known as insulin glargine 300, and was approved as a diabetes treatment in the UK in early 2015.
Its blood sugar-lowering activity lasts beyond 24 hours when taken once a day at the same time each day.
To build on this observational study, researchers are now conducting randomised trials involving more than 4,500 people with type 2 diabetes across Europe and the US who are beginning basal insulin treatment or switching from another basal insulin.

To Top